1. Edition - July 2010
159.- Euro
2010. XXVI, 538 Pages, Hardcover
196 Fig. (23 Colored Fig.), 67 Tab. 
- Handbook/Reference Book -
ISBN-10: 3-527-32549-2
ISBN-13: 978-3-527-32549-8 - Wiley-VCH, Weinheim






Content

Sample Chapter



Short description
Addressing past and current strategies for successful drug analog development, this volume extends its precursor by adding nine analog classes and eight case studies, spanning a variety of therapeutic fields and chemical classes.

From the contents
PART I GENERAL ASPECTS
Optimizing Drug Therapy by Analogues
Standalone Drugs
Application of Molecular Modeling in Analogue-Based Drug Discovery
Issues for the Patenting of Analogues

PART II ANALOGUE CLASSES
Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
Rifamycins, Antibacterial Antibiotics and Their New Applications
Monoterpenoid Indole Alkaloids, CNS Anticancer Drugs
Anthracyclines, Optimizing Anticancer Analogues
Paclitaxel and Epothilone Analogues, Anticancer Drugs
Selective Serotonin Reuptake Inhibitors for the Treatment of Depression
Muscarinic Receptor Antagonists in the Treatment of COPD
beta-Adrenoceptor Agonists and Asthma

PART III CASE HISTORIES
Liraglutide, a GLP-1 Analogue to Treat Diabetes
Eplerenone: Selective Aldosterone Antagonist
Clevudine, to Treat Hepatitis B Viral Infection
Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1
Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV
Lapatinib, an Anticancer Kinase Inhibitor
Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia
Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder